Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment

  • Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting
  • US analysis of long-term financial impact when switching to biosimilar etanercept also presented, modeling significant cost savings for health systems
  • Sandoz is the pioneer and a global leader in biosimilars, with eight approved biosimilars worldwide and more than 10 in the pipeline

Holzkirchen, November 12, 2019 – Sandoz, a Novartis division and a global …

/by

Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment

  • Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting
  • US analysis of long-term financial impact when switching to biosimilar etanercept also presented, modeling significant cost savings for health systems
  • Sandoz is the pioneer and a global leader in biosimilars, with eight approved biosimilars worldwide and more than 10 in the pipeline

Holzkirchen, November 12, 2019 – Sandoz, a Novartis division and a global …

/by

Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market

  • Planned acquisition reinforces Sandoz strategic focus on Japan
  • Aspen portfolio in Japan consists primarily of off-patent branded medicines with focus on anesthetics and specialty brands
  • Medicines complement Sandoz broad hospital portfolio and pipeline in Japan thereby expanding access to the hospital channel

Holzkirchen, Germany, November 11, 2019 – Sandoz today announced that it has entered into a binding agreement for the planned acquisition of the Japanese business of Aspen Global Incorporated …

/by

Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market

  • Planned acquisition reinforces Sandoz strategic focus on Japan
  • Aspen portfolio in Japan consists primarily of off-patent branded medicines with focus on anesthetics and specialty brands
  • Medicines complement Sandoz broad hospital portfolio and pipeline in Japan thereby expanding access to the hospital channel

Holzkirchen, Germany, November 11, 2019 – Sandoz today announced that it has entered into a binding agreement for the planned acquisition of the Japanese business of Aspen Global Incorporated …

/by

Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar ZiextenzoTM (pegfilgrastim-bmez)

  • Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy
     
  • With approval of Ziextenzo™ , Sandoz is first and only company to offer US physicians long- and short-acting filgrastim biosimilar treatment options
     
  • With four US approved biosimilars, Sandoz is committed to expanding patient access, increasing healthcare savings and fueling innovation

Holzkirchen, Nov. 5, 2019 – Sandoz, a Novartis division and a global …

/by

Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar ZiextenzoTM (pegfilgrastim-bmez)

  • Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy
     
  • With approval of Ziextenzo™ , Sandoz is first and only company to offer US physicians long- and short-acting filgrastim biosimilar treatment options
     
  • With four US approved biosimilars, Sandoz is committed to expanding patient access, increasing healthcare savings and fueling innovation

Holzkirchen, Nov. 5, 2019 – Sandoz, a Novartis division and a global …

/by